LAPTM4B and chronic myelogenous leukemia, BCR-ABL1 positive: LAPTM4B (53.33% cases), PIEZO2 (60% cases), ANGPT1 (53.33% cases), CFH (46.66% cases), CD109 (53.33% cases) and HLTF (46.66% cases) molecule were up-regulated in >1% BCR-ABL copies Imatinib-treated CML cases and 57.14%, 14.28%, 57.14%, 6.66%, 0%, 57.14%, HLTF, CFH, CD109, PIEZO2, LAPTM4B and ANGPT1 respectively down-regulated in not detected BCR-ABL copies (Table 4a and 4b).